Do analysts recommend GOSS or NLTX?

Gossamer Bio currently has a consensus price target of $256.00, suggesting a potential upside of 2,414.73%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gossamer Bio 2 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.22 Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is GOSS or STRO more profitable?

Gossamer Bio has a net margin of -235.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets Gossamer Bio -235.00% N/A -112.04% Sutro Biopharma -395.25% N/A -88.12%

Does the media refer more to GOSS or STRO?

In the previous week, Sutro Biopharma had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Sutro Biopharma and 3 mentions for Gossamer Bio. Sutro Biopharma's average media sentiment score of 0.88 beat Gossamer Bio's score of 0.62 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sutro Biopharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, QTTB or GOSS?

Q32 Bio has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Q32 Bio $53.74M 4.43 $29.82M $3.00 2.66 Gossamer Bio $53.29M 1.17 -$170.37M -$56.00 N/A

Is QTTB or GOSS more profitable?

Q32 Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Q32 Bio's return on equity of 50.17% beat Gossamer Bio's return on equity. Company Net Margins Return on Equity Return on Assets Q32 Bio N/A 50.17% 29.49% Gossamer Bio -235.00% N/A -112.04%

Does the media refer more to QTTB or GOSS?

In the previous week, Q32 Bio had 5 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Q32 Bio and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Q32 Bio's score of 0.62 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Q32 Bio 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BCYC or GOSS?

In the previous week, Bicycle Therapeutics had 9 more articles in the media than Gossamer Bio. MarketBeat recorded 12 mentions for Bicycle Therapeutics and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Bicycle Therapeutics' score of -0.10 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicycle Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GALT or GOSS more profitable?

Galectin Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -176.83% Gossamer Bio -235.00% N/A -112.04%

Does the media prefer GALT or GOSS?

In the previous week, Galectin Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 4 mentions for Galectin Therapeutics and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Galectin Therapeutics' score of 0.02 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Galectin Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Gossamer Bio 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Gossamer Bio (GOSS) Competitors

$9.88 -0.30 (-2.95%)

Closing price 04:00 PM Eastern

Extended Trading

$9.82 -0.06 (-0.56%)

As of 06:25 PM Eastern

Compare

GOSS vs. NLTX, STRO, QTTB, BCYC, and GALT

Should you buy Gossamer Bio stock or one of its competitors? Gossamer Bio's main competitors and comparable companies include Neoleukin Therapeutics (NLTX), Sutro Biopharma (STRO), Q32 Bio (QTTB), Bicycle Therapeutics (BCYC), and Galectin Therapeutics (GALT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Gossamer Bio compare to Neoleukin Therapeutics?

Gossamer Bio (NASDAQ:GOSS) and Neoleukin Therapeutics (NASDAQ:NLTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Gossamer Bio currently has a consensus price target of $256.00, suggesting a potential upside of 2,414.73%. Given Gossamer Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Gossamer Bio is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Gossamer Bio has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

In the previous week, Gossamer Bio had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Gossamer Bio and 0 mentions for Neoleukin Therapeutics. Gossamer Bio's average media sentiment score of 0.62 beat Neoleukin Therapeutics' score of 0.00 indicating that Gossamer Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Gossamer Bio	Positive
Neoleukin Therapeutics	Neutral

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. 4.2% of Gossamer Bio shares are owned by company insiders. Comparatively, 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Neoleukin Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$53.29M	1.17	-$170.37M	-$56.00	N/A
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A

Neoleukin Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Gossamer Bio's return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Neoleukin Therapeutics	N/A	-37.22%	-30.91%

Summary

Gossamer Bio beats Neoleukin Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Gossamer Bio compare to Sutro Biopharma?

Gossamer Bio (NASDAQ:GOSS) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Sutro Biopharma had 2 more articles in the media than Gossamer Bio. MarketBeat recorded 5 mentions for Sutro Biopharma and 3 mentions for Gossamer Bio. Sutro Biopharma's average media sentiment score of 0.88 beat Gossamer Bio's score of 0.62 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sutro Biopharma	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gossamer Bio has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$53.29M	1.17	-$170.37M	-$56.00	N/A
Sutro Biopharma	$102.48M	2.37	-$191.09M	-$11.97	N/A

Gossamer Bio has a net margin of -235.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-235.00%	N/A	-112.04%
Sutro Biopharma	-395.25%	N/A	-88.12%

Gossamer Bio has a beta of 2.21, suggesting that its share price is 121% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Gossamer Bio currently has a consensus target price of $256.00, suggesting a potential upside of 2,414.73%. Sutro Biopharma has a consensus target price of $49.50, suggesting a potential upside of 237.65%. Given Gossamer Bio's higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Sutro Biopharma beats Gossamer Bio on 10 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Q32 Bio?

Q32 Bio (NASDAQ:QTTB) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Q32 Bio has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%. Q32 Bio's return on equity of 50.17% beat Gossamer Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Q32 Bio	N/A	50.17%	29.49%
Gossamer Bio	-235.00%	N/A	-112.04%

31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 34.5% of Q32 Bio shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Q32 Bio presently has a consensus target price of $30.60, indicating a potential upside of 282.98%. Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,414.73%. Given Gossamer Bio's higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.88
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Q32 Bio had 5 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Q32 Bio and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Q32 Bio's score of 0.62 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Q32 Bio	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Q32 Bio has higher revenue and earnings than Gossamer Bio. Gossamer Bio is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Q32 Bio	$53.74M	4.43	$29.82M	$3.00	2.66
Gossamer Bio	$53.29M	1.17	-$170.37M	-$56.00	N/A

Q32 Bio has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, indicating that its stock price is 121% more volatile than the broader market.

Summary

Q32 Bio beats Gossamer Bio on 13 of the 17 factors compared between the two stocks.

How does Gossamer Bio compare to Bicycle Therapeutics?

Bicycle Therapeutics (NASDAQ:BCYC) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Bicycle Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 22.0% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bicycle Therapeutics had 9 more articles in the media than Gossamer Bio. MarketBeat recorded 12 mentions for Bicycle Therapeutics and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Bicycle Therapeutics' score of -0.10 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicycle Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Gossamer Bio has a net margin of -235.00% compared to Bicycle Therapeutics' net margin of -311.11%. Gossamer Bio's return on equity of 0.00% beat Bicycle Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicycle Therapeutics	-311.11%	-33.22%	-27.79%
Gossamer Bio	-235.00%	N/A	-112.04%

Bicycle Therapeutics currently has a consensus price target of $13.86, suggesting a potential upside of 271.51%. Gossamer Bio has a consensus price target of $256.00, suggesting a potential upside of 2,414.73%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Bicycle Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicycle Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Gossamer Bio has lower revenue, but higher earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicycle Therapeutics	$72.86M	3.58	-$218.96M	-$2.73	N/A
Gossamer Bio	$53.29M	1.17	-$170.37M	-$56.00	N/A

Summary

Bicycle Therapeutics beats Gossamer Bio on 9 of the 16 factors compared between the two stocks.

How does Gossamer Bio compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and Gossamer Bio (NASDAQ:GOSS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Galectin Therapeutics has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Gossamer Bio has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market.

Galectin Therapeutics presently has a consensus target price of $11.00, indicating a potential upside of 203.87%. Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,414.73%. Given Gossamer Bio's stronger consensus rating and higher possible upside, analysts clearly believe Gossamer Bio is more favorable than Galectin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Gossamer Bio	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Galectin Therapeutics had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 4 mentions for Galectin Therapeutics and 3 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.62 beat Galectin Therapeutics' score of 0.02 indicating that Gossamer Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Galectin Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gossamer Bio	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Galectin Therapeutics has higher earnings, but lower revenue than Gossamer Bio. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.43	N/A
Gossamer Bio	$53.29M	1.17	-$170.37M	-$56.00	N/A

11.7% of Galectin Therapeutics shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 52.6% of Galectin Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Galectin Therapeutics has a net margin of 0.00% compared to Gossamer Bio's net margin of -235.00%.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-176.83%
Gossamer Bio	-235.00%	N/A	-112.04%

Summary

Gossamer Bio beats Galectin Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Gossamer Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GOSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GOSS vs. The Competition

Export

Metric	Gossamer Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$60.38M	$3.83B	$7.14B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	16.47%
P/E Ratio	-0.18	13.96	275.15	25.94
Price / Sales	1.13	1,177.93	566.78	83.59
Price / Cash	N/A	118.37	77.41	52.81
Price / Book	-0.23	16.11	10.80	6.27
Net Income	-$170.37M	-$22.69M	$3.50B	$382.13M
7 Day Performance	-9.61%	-3.47%	-2.02%	-1.39%
1 Month Performance	-31.35%	-12.68%	-7.54%	-5.62%
1 Year Performance	-94.90%	9.60%	3.31%	-1.54%

Gossamer Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GOSS Gossamer Bio	2.9485 of 5 stars	$9.88 -2.9%	$256.00 +2,491.1%	-94.9%	$60.38M	$53.29M	N/A	162
NLTX Neoleukin Therapeutics	N/A	$28.31 -9.4%	N/A	+10.2%	$266.06M	N/A	N/A	90	High Trading Volume
STRO Sutro Biopharma	3.2705 of 5 stars	$16.03 +0.3%	$47.30 +195.1%	+74.0%	$264.97M	$102.48M	N/A	128	Positive News
QTTB Q32 Bio	3.6679 of 5 stars	$9.23 +5.2%	$30.60 +231.5%	+217.1%	$261.08M	$53.74M	3.08	22	Positive News Analyst Revision
BCYC Bicycle Therapeutics	2.2763 of 5 stars	$3.71 +0.8%	$13.86 +273.5%	-53.4%	$257.92M	$72.86M	N/A	288

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GOSS) was last updated on 10/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gossamer Bio (GOSS) Competitors

GOSS vs. NLTX, STRO, QTTB, BCYC, and GALT

How does Gossamer Bio compare to Neoleukin Therapeutics?

Summary

How does Gossamer Bio compare to Sutro Biopharma?

Summary

How does Gossamer Bio compare to Q32 Bio?

Summary

How does Gossamer Bio compare to Bicycle Therapeutics?

Summary

How does Gossamer Bio compare to Galectin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gossamer Bio (GOSS) Competitors

GOSS vs. NLTX, STRO, QTTB, BCYC, and GALT

How does Gossamer Bio compare to Neoleukin Therapeutics?

Do analysts recommend GOSS or NLTX?

Which has more risk & volatility, GOSS or NLTX?

Does the media refer more to GOSS or NLTX?

Do insiders and institutionals hold more shares of GOSS or NLTX?

Which has higher earnings and valuation, GOSS or NLTX?

Is GOSS or NLTX more profitable?

Summary

How does Gossamer Bio compare to Sutro Biopharma?

Does the media refer more to GOSS or STRO?

Do insiders & institutionals hold more shares of GOSS or STRO?

Which has better earnings and valuation, GOSS or STRO?

Is GOSS or STRO more profitable?

Which has more volatility & risk, GOSS or STRO?

Do analysts rate GOSS or STRO?

Summary

How does Gossamer Bio compare to Q32 Bio?

Is QTTB or GOSS more profitable?

Do institutionals and insiders believe in QTTB or GOSS?

Do analysts prefer QTTB or GOSS?

Does the media refer more to QTTB or GOSS?

Which has higher earnings & valuation, QTTB or GOSS?

Which has more volatility & risk, QTTB or GOSS?

Summary

How does Gossamer Bio compare to Bicycle Therapeutics?

Which has more volatility and risk, BCYC or GOSS?

Do insiders & institutionals hold more shares of BCYC or GOSS?

Does the media favor BCYC or GOSS?

Is BCYC or GOSS more profitable?

Do analysts rate BCYC or GOSS?

Which has better valuation and earnings, BCYC or GOSS?

Summary

How does Gossamer Bio compare to Galectin Therapeutics?

Which has more volatility and risk, GALT or GOSS?

Do analysts recommend GALT or GOSS?

Does the media prefer GALT or GOSS?

Which has preferable valuation & earnings, GALT or GOSS?

Do institutionals and insiders have more ownership in GALT or GOSS?

Is GALT or GOSS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS vs. The Competition

Gossamer Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools